Myeloperoxidase is not associated with scintigraphic myocardial perfusion abnormalities in type 2 diabetic patients with mild stable anginal complaints

详细信息    查看全文

• 作者：Jacobijne J. Wiersma ; Hein J. Verberne ; Marijn C. Meuwese ; Erik S.G. Stroes ; Joram N.I. van Miert ; Berthe L.F. van Eck-Smit ; Jan G.P. Tijssen ; Jan J. Piek ; Mieke D. Trip
• 关键词：Myeloperoxidase ; Diabetes mellitus type 2 ; Myocardial ischemia ; Myocardial perfusion scintigraphy
• 刊名：Clinica Chimica Acta
• 出版年：2011
• 出版时间：14 January 2011
• 年：2011
• 卷：412
• 期：1-2
• 页码：86-90
• 全文大小：159 K

文摘

Background

MPO, an enzyme of the innate immune system, exhibits pro-atherogenic effects. These include oxidative damage to LDL- and HDL-cholesterol, and promotion of endothelial dysfunction. Recent studies revealed that MPO independently predicts adverse outcomes in patients with chest pain or suspected acute coronary syndrome. We evaluated whether plasma myeloperoxidase (MPO) levels are associated with scintigraphic myocardial perfusion abnormalities, in type 2 diabetic patients with mild anginal complaints.

Methods

MPO was measured in plasma samples of 267 patients with diabetes mellitus type 2 and stable angina pectoris complaints (Canadian Cardiovascular Society class I–II/IV) prior to myocardial perfusion scintigraphy (MPS).

Results

The median plasma level of MPO was 141 pmol/L (IQR 115–171 pmol/L). One-hundred-ninety patients (71 % ) had perfusion abnormalities on MPS and of these, 138 patients had myocardial ischemia. No relation was found between plasma MPO levels and the scintigraphic myocardial perfusion abnormalities. Even in combination with known other cardiovascular risk factors MPO failed to predict scintigraphic myocardial perfusion abnormalities.

Conclusions

MPO levels are not associated with scintigraphic myocardial perfusion abnormalities in type 2 diabetic patients with mild anginal complaints. Therefore, in type 2 diabetic patients MPO is not a useful biomarker to predict hemodynamically significant coronary artery disease.